Lupin gets USFDA nod for hypertension treatment drug in US

Published On 2016-12-27 06:02 GMT   |   Update On 2016-12-27 06:02 GMT

New Delhi : Drug major Lupin has received tentative approval from the US health regulator to sell Olmesartan medoximil tablets, used for treating high blood pressure, in the American market.


"It has received tentative (rpt) tentative approval for Olmesartan medoximil tablets, 5 mg, 20 mg and 40 mg from the US Food and Drug Administration (USFDA)," Lupin Ltd said in a BSE filing.


Olmesartan medoximil tablets, generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents to lower blood pressure, it added.


Quoting IMS MAT September 2016 sales data, Lupin further said that Benicar tablets had annual US sales of USD 1.06 billion.


Shares of the company were trading 0.71 per cent up at Rs 1,457 apiece on BSE.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News